Discordance analysis and the Gordian Knot of LDL and non-HDL cholesterol versus apoB

Six years after his opening manifesto, Sniderman and colleagues sharpen the ApoB argument into a method: discordance analysis, a clean way to settle whether cholesterol mass or particle number better predicts risk.

The logic is elegant. When two markers usually agree, you can’t tell which one matters; the test is what happens in the minority of patients where they disagree. By isolating those discordant cases — where ApoB and LDL-C point in different directions — the authors show that risk consistently tracks the particle count (ApoB or LDL particle number), not the cholesterol mass (LDL-C or non-HDL-C).

The practical takeaway is to use ApoB or particle number, especially where it would diverge from LDL-C, to avoid under- or over-treating. The resistance is the persistence of LDL-C in guidelines despite this methodological clarity.

We rate the evidence moderate: a rigorous methodological review with consistent findings across studies and no declared conflicts, though a review rather than primary data. Its clinical significance is moderate-to-high — discordance analysis is the conceptual tool that turned the ApoB-versus-cholesterol debate from opinion into something testable, and it consistently favors particle number.